Delivery Order SPE2DB22D1202-SPE2DB25FUVL9

Award Date 3/19/25
Potential Completion Date 4/9/25
Potential Value $2.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $5,263.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of March 15, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,527.36 firm fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialty pharmaceutical product. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,648.75 firm fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialty medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This federal contract award, with a ceiling value of $9,297.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, a medical product used for various treatments. The contract is a firm fixed-price delivery order, with a period of performance through May 30, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,509.16 to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of June 13, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $21,932 firm fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS medical devices. The contract has an ultimate completion date of August 13, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,631.84, is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialized pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of March 12, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $8,772.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialized pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order with a firm fixed price and a ceiling value of $1,859.50. The contract is not set aside and will deliver ZOLADEX 10.8 MG IMPLANT SYRNS to the government. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a $9,297.50 firm-fixed-price delivery order for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS medical devices. The contract is awarded by the Defense Logistics Agency (DLA), a defense agency, and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUVL9
    Delivery Order

This federal contract award, valued at $2,789.25, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, a medical product, to support military healthcare programs.

The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract does not have a set-aside designation, indicating open competition.

Generated 6/18/25, 11:01 AM